JAK3

Across TCGA pan-cancer cohorts, JAK3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated JAK3 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher JAK3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated JAK3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where JAK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.333	1.000	.010	6	view →
GBM	DFS	Tertile	All	0.206	0.404	.023	4	view →
CCRCC	DFS	Tertile	All	0.978	0.509	.013	4	view →
HNSC	OS	Median	III,IV	1.000	0.945	.037	2	view →
LSCC	DFS	Quartile	All	0.815	0.369	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

JAK3–PDAC (OS)

Open the PDAC breakdown →